Journal: Drug Design, Development and Therapy
Article Title: Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents
Figure Lengend Snippet: Representative chromatograms of LASSBio-1771 (8) (20 µM) and its metabolite formed by incubation with rat plasma. Notes: ( A ) Incubation in rat plasma at 0 minute; ( B ) incubation in rat plasma at 1 hour, and appearance of metabolite (M) formed at 4.57 minutes; ( C ) HPLC/MS ion scan of M [M-H] − at m/z 363.09 (retention time at 4.57); ( D ) UV chromatogram of M at 4.57 minutes; ( E ) co-injection of synthesized standard M (10) in 1 hour rat plasma experiment (M); ( F ) UV chromatogram of standard (10) at 4.57 minutes. IS: internal standard (eg, methyl biphenyl-4-carboxylate, C =20 µM). Apparatus: Shimadzu – LC20AD, column: Kromasil 100-5 C18 250 to 4.6 mm. Mobile phase: 50% acetonitrile, 50% water-gradient, 0.1% formic acid, flow: 1 mL/min. Detector: SPD-M20A (Diode Array); wavelength: 254 nm. The mass spectrometer analyses were performed by the mass spectrometer model Esquire 6000 – ESI Ion Trap MSn System Bruker Daltonics (LASSBio ® -UFRJ). Abbreviations: HPLC/MS, high performance liquid chromatography/mass spectrometry; min, minutes; UV, ultraviolet spectroscopy; Intens, Intensity.
Article Snippet: HPLC-UV analysis The organic fraction was analyzed with the Shimadzu Prominence HPLC system (Shimadzu, Tokyo, Japan) consisting of a vacuum degasser (DGU-20A5), a binary pump (LC-20AD), an autosampler (SIL-20A), UV/VIS Photodiode Array Detector (SPD-M20A), and fitted with a guard column (CLC G-ODS) and Kromasil 100-5C18 (4.6×250 mm) analytical column running at room temperature.
Techniques: Incubation, High Performance Liquid Chromatography, Mass Spectrometry, Injection, Synthesized, Flow Cytometry, Spectroscopy